Efficacy of a Physical and Respiratory Rehabilitation Program for Patients With Persistent COVID-19 (SARS-CoV-2). — COPERIA-REHAB  

Fatigue Clinical Trial

Official title: Efficacy of a Physical and Respiratory Rehabilitation Program (COPERIA-REHAB) for Patients With Persistent COVID-19 (SARS-CoV-2).

Status Not yet recruiting

Clinical Trial Summary

The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of a plethora of persistent, diffuse and heterogeneous symptoms such as fatigue, shortness of breath and cognitive dysfunction among others, that have come to be called persistent COVID. Patients have reported that physical activity, stress and sleep disturbances often trigger exacerbations of their symptoms related by some authors to the so-called Post Exertional Malaise (PEM) characteristic of Myalgic Encephalomyelitis. Similarly, by analogy with other pathologies, it has been hypothesized that optimal exercise prescription would benefit these people with persistent COVID-19 symptoms but in practice, the rehabilitation of these patients runs the risk of collapsing respiratory and physical rehabilitation services.

This is why COPERIA proposes the construction of a platform for respiratory, cardiac and muscular telerehabilitation, to compare with face-to-face rehabilitation treatment and to try to predict the influence of physical activity in the prediction of PEM.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cognitive Dysfunction
• COVID-19
• Fatigue
• SARS-CoV-2 Infection

• NCT number: NCT05629884
• Study type: Interventional
• Source: Fundacin Biomedica Galicia Sur
• Contact: Alejandro García Caballero, MD
• Phone: 988 38 55 00
• Email: alejandro.alberto.garcia.caballero@sergas.es
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 14, 2022
• Completion date: November 14, 2023